CA
ALNY icon

Cetera Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cetera Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$238K Buy
+1,593
New +$266K ﹤0.01% 2102
2014
Q1 		– Sell
-3,145
Closed -$203K – 546
2013
Q4 		$203K Sell
3,145
-5,630
-64% -$336K 0.03% 459
2013
Q3 		$562K Buy
+8,775
New +$437K 0.1% 223

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cetera Advisors's ALNY Position: Q1 2024 in Review

Cetera Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2024: 1,593 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #2102 among its holdings. This is a return to the name: Cetera Advisors previously reported a position in ALNY as recently as Q4 2013.

Cetera Advisors first reported a position in ALNY in Q3 2013 and has held it in 3 quarters since. The position peaked at $562K in Q3 2013. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Cetera Advisors held 1,593 shares of Alnylam Pharmaceuticals worth $238K as of Q1 2024.
  • Alnylam Pharmaceuticals was a new Cetera Advisors position in Q1 2024.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #2102 holding.
  • Cetera Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
  • Cetera Advisors's Alnylam Pharmaceuticals position peaked at $562K in Q3 2013.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.